An interventional study of Remote speech rehabilitation in Parkinson Disease and Dysarthria, sponsored by Florida State University. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Florida State University · Not applicable, Interventional, and Treatment
This study develops and conduct a small-scale clinical trial study in which the linguistic and cultural diversity of the participants is considered. Speech therapy and counseling services are provided to both patients with Parkinson\'s disease and their caregivers.
Attention has been increasingly paid to the "culturally and linguistically diverse (CLD)" communities which typically include dialectal users of English, monolingual and multilingual speakers of minority languages, and bilingual speakers of English and a minority language. However, among these, monolingual speakers of minority languages living in the US have been nearly excluded from dysarthria management. Most of these are first-generation immigrants who are well documented to have limited access to financial and medical services and have poorer health outcomes including communication difficulties. This creates critical health disparities in the field of communication rehabilitation.
This study will (1) examine effects of speech therapy on PD patients' speech acoustics and intelligibility, (2) examine effects of the intervention program on communication participation and well-being of both PD patients and their families. Our primary outcome measures, speech intelligibility and acoustic measures, are hypothesized to show improvements. Acoustic predictors of speech intelligibility are expected to include acoustic vowel space and voice onset time. These hypotheses are based on literature reporting (1) positive changes in speech function after intensive treatment programs focusing on vocal effort and hyperarticulation and (2) language-specific contributors to speech intelligibility in PD. Our secondary outcome measures include (1) communication participation and (2) well-being measures which will be obtained from both PD patients and family members. Based on previous research, the measures are hypothesized to show improved communication participation and well-being in both PD patients and their families following therapy.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's planned enrollment of 32 is below the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Florida State University is the lead sponsor of 249 studies on the registry; 47 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks, including two components: family counseling (30 min) and family conversation training (30 min). Family counseling aims to increase the PD families' knowledge about PD in general and to identify goals and potential solutions to problems which cause emotional turmoil. Family conversation training which aims to increase the PD families' knowledge about PD-related communication problems and to raise awareness of their communication patterns, and to support the development of functional strategies. All activities will remotely occur (using Zoom).
Behavioral: Remote speech rehabilitation
No intervention programs (speech therapy, counseling) will be provided.
Two types of intervention will be provided via online to 32 dyads of people with Parkinson's disease: (1) speech therapy (PD patients) and (2) family education/training (PD families). Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks.
Speech Intelligibility Score on a Visual Analogue Scale
Speech intelligibility will be estimated using the visual analogue scale method. Listeners will rate the degree to which they understood the speech recordings on a continuous line. The two ends will be labeled, totally unintelligible and completely intelligible, respectively. Higher scores indicate more intelligible.
Time frame: Immediately after and 6 months after treatment
Vowel Space Area (kHz)
Two acoustic measures will be measured as Primary Outcome. The first one is the size of vowel space area, which has been frequently reported to correlate with speech intelligibility in people with Parkinson's disease.
Time frame: Immediately after and 6 months after treatment
Speaking Rate (syl/s)
The second acoustic measures to be included as Primary Outcome is speaking rate. This will be reported as the number of syllables produced in one second.
Time frame: Immediately after and 6 months after treatment
Dysarthria Impact Profile (DIP)
DIP is an assessment tool designed to measure the psychosocial impact of dysarthria on affected individuals. It consists of several sections with statements rated on a five-point scale, ranging from "strongly agree" to "strongly disagree." DIP incorporates positively and negatively worded statements with differing scoring schemes. This will be obtained from people with Parkinson's disease. Higher scores indicate greater impact of dysarthria.
Time frame: Immediately after and 6 months after treatment
Everyday Communication Measure
Family members will also be asked to rate five different aspects of the PD participant's everyday communication abilities using Everyday Communication Measures on a scale of 1 (poor) to 7 (very good). Example questions include, "how easy is it to understand the speaker?" and "how often does the speaker initiate conversation with you?". This will be obtained from family members of PD participants. Lower scores indicate greater difficulties of everyday communication.
Time frame: Immediately after and 6 months after treatment
Quality of Family Life Scale
The Family Quality of Life Scale (FQOL) is a 25-item instrument used to measure several aspects of families' perceived satisfaction in terms of quality of family life (e.g., family interaction, emotional well-being, physical/material well-being, and disability-related support). It uses a 1(very dissatisfied)-5 (very satisfied) Likert scale. Higher scores indicated a better quality of family life.
Time frame: Immediately after and 6 months after treatment
Perceived Stress Scale
The Perceived Stress Scale (PSP) will be used for measuring psychological stress. Among the three versions of the PSS, the Korean version of PSS-10 will be used. It uses a 0 (never)-4 (very often) Likert scale. Higher scores indicate more stress.
Time frame: Immediately after and 6 months after treatment
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.